🚀 VC round data is live in beta, check it out!
Brightgene Bio-medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Brightgene Bio-medical and similar public comparables like Camurus, Almirall, Dyne Therapeutics, Oruka Therapeutics and more.
Brightgene Bio-medical Overview
About Brightgene Bio-medical
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Founded
2001
HQ
Employees
N/A
Website
Financials (FY)
EV
$3B
Brightgene Bio-medical Financials
Brightgene Bio-medical reported last fiscal year revenue of $179M and EBITDA of $35M.
In the same fiscal year, Brightgene Bio-medical generated $91M in gross profit, $35M in EBITDA, and $8M in net income.
Revenue (LTM)
Brightgene Bio-medical P&L
In the most recent fiscal year, Brightgene Bio-medical reported revenue of $179M and EBITDA of $35M.
Brightgene Bio-medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $179M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $91M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 51% | XXX | XXX | XXX |
| EBITDA | — | XXX | $35M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 9% | XXX | XXX | XXX |
| Net Profit | — | XXX | $8M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $79M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Brightgene Bio-medical Stock Performance
Brightgene Bio-medical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Brightgene Bio-medical's stock price is $7.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -0.6% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBrightgene Bio-medical Valuation Multiples
Brightgene Bio-medical trades at 18.8x EV/Revenue multiple, and 97.5x EV/EBITDA.
EV / Revenue (LTM)
Brightgene Bio-medical Financial Valuation Multiples
As of April 11, 2026, Brightgene Bio-medical has market cap of $3B and EV of $3B.
Equity research analysts estimate Brightgene Bio-medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Brightgene Bio-medical has a P/E ratio of 397.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 18.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 97.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 209.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 37.1x | XXX | XXX | XXX |
| P/E | — | XXX | 397.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (179.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Brightgene Bio-medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Brightgene Bio-medical Margins & Growth Rates
Brightgene Bio-medical's revenue in the last fiscal year declined by (5%).
Brightgene Bio-medical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (26%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Brightgene Bio-medical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| Almirall | XXX | XXX | XXX | XXX | XXX | XXX |
| Dyne Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oruka Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunshine Lake Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Brightgene Bio-medical M&A Activity
Brightgene Bio-medical acquired XXX companies to date.
Last acquisition by Brightgene Bio-medical was on XXXXXXXX, XXXXX. Brightgene Bio-medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Brightgene Bio-medical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBrightgene Bio-medical Investment Activity
Brightgene Bio-medical invested in XXX companies to date.
Brightgene Bio-medical made its latest investment on XXXXXXXX, XXXXX. Brightgene Bio-medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Brightgene Bio-medical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Brightgene Bio-medical
| When was Brightgene Bio-medical founded? | Brightgene Bio-medical was founded in 2001. |
| Where is Brightgene Bio-medical headquartered? | Brightgene Bio-medical is headquartered in China. |
| Is Brightgene Bio-medical publicly listed? | Yes, Brightgene Bio-medical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Brightgene Bio-medical? | Brightgene Bio-medical trades under 688166 ticker. |
| When did Brightgene Bio-medical go public? | Brightgene Bio-medical went public in 2019. |
| Who are competitors of Brightgene Bio-medical? | Brightgene Bio-medical main competitors are Camurus, Almirall, Dyne Therapeutics, Oruka Therapeutics. |
| What is the current market cap of Brightgene Bio-medical? | Brightgene Bio-medical's current market cap is $3B. |
| What is the current revenue of Brightgene Bio-medical? | Brightgene Bio-medical's last fiscal year revenue is $179M. |
| What is the current EV/Revenue multiple of Brightgene Bio-medical? | Current revenue multiple of Brightgene Bio-medical is 18.8x. |
| Is Brightgene Bio-medical profitable? | No, Brightgene Bio-medical is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.